The State of Play in Experience Design

Whether you’re an integrator, a designer or simply a label-defying creative, the EXPERIENCE is everything. Host Bryan Meszaros explores the story behind the exhibit to understand how a carefully crafted experience traps into the human experience to connect people to place.

 

Catch up with Experience by Design host Bryan Meszaros. He offered thoughts on past conversations, upcoming conversations, and how experience design is quickly evolving. “Starting this podcast was a way to share the conversations I’d been having. There are so many insights that are important to capture.”

Meszaros shared his excitement to experience new things as the world begins to open up, creating a bucket list. He also wants to further the conversation on how digital engagement and technology are shaping experiences of the future. One thing he was adamant about is that “you have to create a reason for people to come to you.”

Those emerging from the pandemic aren’t the same as before. Meszaros shared some things that resonated with him from an article. “Consumers want connectivity and community. The challenge for experience designers is how to create reconnection.”

That’s true of retail, hospitality, and so many other spaces. In retail, getting shoppers in stores is less about the product and more about experiencing some element of that brand.

“Buying behaviors have shifted, and consumers are demanding more immersive experience, and they should. This is the moment to apply data and technology to address these shifts. They want something they can’t get at home.”

It’s time for more creativity and seamlessly integrating technology and digital media to create unique and enticing environments.

Join host Bryan Meszaros on Experience by Design every other Wednesday as he explores the latest trends and solutions, helping craft the world’s most intriguing experiences.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More